Deals this week: Keros Therapeutics, Opollomics, CANbridge

11th January 2019 (Last Updated January 11th, 2019 00:00)

Keros Therapeutics has raised $23m in series B funding round.

Keros Therapeutics has raised $23m in a series B funding round.

Existing investors Pontifax, Arkin Bio Ventures, Partners Innovation Fund, and Medison Pharma participated in the funding round along with new investor Global Health Sciences Fund.

The new investment has raised the company’s total venture funding to $34m.

Proceeds will be utilised to progress Keros’ two lead drug candidates into clinical trials.

Keros Therapeutics is a pharmaceutical company based in the US.

Axsome Therapeutics has raised $23.3m by selling 2.8 million shares under an existing at-the-market (ATM) facility signed with Leerink Partners.

It will use the proceeds to develop novel therapies for central nervous system disorders and perform ongoing clinical trials of drug candidates as well as support future clinical programmes.

Axsome is a biopharmaceutical company, while Leerink Partners is a healthcare-focused investment bank.

"Axsome Therapeutics has raised $23.3m by selling 2.8 million shares under an existing at-the-market facility signed with Leerink Partners."

Both the companies involved in the transaction are based in the US.

Stelexis Therapeutics has secured $43m in a series A funding round.

The company will use the proceeds to further develop its novel proprietary platform to discover and develop cancer therapeutics.

This platform will identify the pre-cancerous stem cells that lead to malignant tumour formation and cancer relapse.

Stelexis is a biopharmaceutical company based in the US.

Apollomics has raised $100m in a series B funding round led by CMB International.

Existing investor OrbiMed Asia and several new investors also participated in the round.

The proceeds will be used towards the development of new candidates and for advancing existing oncology programmes.

Apollomics is an American biopharmaceutical company.

CANbridge Pharmaceuticals has signed a licensing agreement with GC Pharma to commercialise Hunterase™ in China.

Hunterase™ is a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy indicated for the treatment of Hunter syndrome.

CANbridge and GC Pharma are biopharmaceutical companies based in China and South Korea respectively.